Asosiy kontentga oʻtish
Boshqa

EXPERIMENTAL MODELS OF PARKINSONISM IN THE SCREENING OF NOVEL ANTIPARKINSONIAN AGENTS: A COMPARATIVE ANALYSIS OF THEIR CAPABILITIES, LIMITATIONS AND THE CHOICE OF BEHAVIOURAL ENDPOINTS

K.K. Akhmadjonov¹¹Tashkent Pharmaceutical Institute, Tashkent, Uzbekistan,Azizbek Azamatov²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, UzbekistanU.A. Kurbonov²²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, UzbekistanSherzod Zhurakulov²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uzbekistan, Tashkent, UzbekistanWorldly Knowledge Publishing Centre
2026
Ochiq kirishYashil

Litsenziya: cc-by

ABI

Annotatsiya

The validity of any conclusion regarding the antiparkinsonian activity of a new compound is determined primarily by the experimental model selected and by the behavioural endpoints used to record the effect. The present review compares the four models of parkinsonian syndrome most widely applied in preclinical screening practice — haloperidol-induced catalepsy, reserpine-induced oligokinesia, the chronic rotenone model and the unilateral 6-hydroxydopamine (6-OHDA) model. The models are examined against a uniform set of criteria: the pathogenetic link targeted; the reversibility and depth of the resulting dopamine deficiency; the time course of syndrome development; the species and age of the animals; the available outcome measures; reproducibility; and the vulnerable points of interpretation. It is shown that models of reversible pharmacological blockade (haloperidol, reserpine) and models of structural neurodegeneration (rotenone, 6-OHDA) answer fundamentally different questions and are not interchangeable: the former permit rapid detection of a dopaminergic or anticholinergic component in the spectrum of action of a compound, whereas the latter allow the ability of a compound to limit neuronal loss to be tested. The informative value of the behavioural tests is analysed separately, together with the typical methodological errors that invalidate an otherwise sound result — in particular the use of parametric statistics for ordinal rating scales and the failure to control for non-specific stimulation of locomotion. A four-stage scheme for the sequential narrowing of the compound set is proposed, in which each successive stage increases the pathogenetic proximity of the model to the disease while the number of compounds under study decreases.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

0 ta iqtibos0 ta foydalanilgan manba